Evidence map›Paper›PMID 41118000›Full record

ArticleJournal of neurology2025

Outcomes of GLP-1 receptor agonist use following ischemic stroke: a propensity score-matched real-world analysis.

Pranjal Rai, Girish Bathla, Niharika Praveen, Shreya Sri Gopikonda, Huanwen Alvin Chen, Hamza A Salim, Ahmed Azzam, Muhammed Amir Essibayi, David J Altschul, Adam A Dmytriw and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Pranjal RaiDepartment of Radiology, Mayo Clinic, 200 1St Street Southwest, Rochester, MN, 55905, USA. rai.pranjal@mayo.edu.ORCID http://orcid.org/0009-0008-3796-8273
Girish BathlaDepartment of Radiology, Mayo Clinic, 200 1St Street Southwest, Rochester, MN, 55905, USA.
Niharika PraveenDepartment of Radiology, Mayo Clinic, 200 1St Street Southwest, Rochester, MN, 55905, USA.
Shreya Sri GopikondaEmployee State Insurance Corporation (ESIC) Hospital, 65 Sanjeeva Reddy Nagar, Sanath Nagar, Hyderabad, Telangana, 500038, India.
Huanwen Alvin ChenDepartment of Neurosurgery, University of Maryland Medical Center, Baltimore, MD, USA.
Hamza A SalimDepartment of Neuroradiology, MD Anderson Medical Center, Houston, TX, USA.
Ahmed AzzamDepartment of Neurological Surgery and Montefiore-Einstein Cerebrovascular Research Lab, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Muhammed Amir EssibayiDepartment of Neurological Surgery and Montefiore-Einstein Cerebrovascular Research Lab, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
David J AltschulDepartment of Neurological Surgery and Montefiore-Einstein Cerebrovascular Research Lab, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Adam A DmytriwNeuroendovascular Program, Massachusetts General Hospital, Harvard University, Boston, MA, USA.
Vivek S YedavalliDepartment of Radiology, Johns Hopkins Medical Center, Baltimore, MD, USA.
Shahrzad LatifiDepartment of Neurosciences, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV, USA.
Ajay MalhotraDepartment of Radiology, Yale New Haven Hospital, New Haven, CT, USA.
Marco ColasurdoDepartment of Interventional Radiology, Oregon Health & Science University Hospital, Portland, OR, USA.
Dheeraj GandhiDepartment of Neurosurgery, University of Maryland Medical Center, Baltimore, MD, USA.
Dhairya A LakhaniDepartment of Neurosciences, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlucagon-like peptide-1 receptor agonists (GLP-1As) have been shown to be beneficial in primary stroke prevention for high-risk patients. However, their benefits following major ischemic events are unclear. Herein, we present real-world analysis assessing outcomes of GLP-1A following major ischemic event.

methodsThis retrospective cohort study utilized the TriNetX platform. Adults (≥ 18 years) with AIS treated with intravenous thrombolysis (IVT) were identified; exposure was any US FDA-approved GLP-1A initiated within 6 months of the index stroke. The comparator was IVT-treated patients without GLP-1A exposure. Outcomes assessed at 5 years included major adverse health-care events (MAHEs): number of emergency department (ED) visits and inpatient hospitalizations, and all-cause mortality. One-to-one propensity score matching balanced baseline characteristics. We estimated risk difference/risk ratio/odds ratio, 5-year Kaplan-Meier (KM) event probabilities with log-rank tests, and Cox hazard ratios (HRs) with 95% CIs; small cells (≤ 10) were masked per data-use agreement.

resultsOf 69,005 eligible patients, 549 received GLP-1A and 68,938 did not; after matching, 432 per group were analyzed. GLP-1A exposure was associated with lower all-cause mortality (7.4% vs 14.1%; HR 0.61, 95% CI 0.39-0.93), lower ED visits (37% vs 47%; HR 0.78, 95% CI 0.63-0.95), and lower inpatient hospitalizations (31.9% vs 45.4%; HR 0.69, 95% CI 0.55-0.85); KM log-rank p ≤ 0.05 for all. Median time to first MAHE was longer with GLP-1A (1293 vs 897 days for hospitalization and 886 vs 603 days for ED visits).

conclusionsGLP-1A therapy after IVT is associated with favorable long-term safety and utilization signals and warrants confirmation in a prospective study with standardized initiation.

Indexed as

Glucagon-Like Peptide-1 Receptor AgonistsIschemic StrokeAgedAged, 80 and overCohort StudiesEmergency Service, HospitalFemaleHospitalizationHumansMaleMiddle AgedPropensity ScoreRetrospective StudiesThrombolytic TherapyTreatment OutcomeGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-like peptide 1 receptor agonistsIntracranial hemorrhagesStrokeThrombolytic therapyTransient ischemic attack

Identifiers

PMID41118000

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.